Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EquipNet to Discuss Asset Management Systems at Interphex 2014

Published: Friday, March 14, 2014
Last Updated: Friday, March 14, 2014
Bookmark and Share
Visit EquipNet on Booth #1239.

Experts from EquipNet Inc. will be on hand at Interphex 2014 (18-20 March in New York City) to demonstrate and discuss the company’s unique asset management solution.

The industry-leading company is dedicated to the pharmaceutical, biotechnology and chemical markets; helping businesses redeploy or sell idle or surplus analytical instruments, process pilot, laboratory, and packaging equipment.

Asset management has evolved in recent years, with surveys showing companies have, on average, 5% of their assets lying idle. EquipNet has been at the forefront of these changes and now offers its clients a range of workflow and management solutions to aid redeployment or sale of business assets.

Their web-based system, ARMS™ (Asset Redeployment Management System) sits behind a company’s firewall, efficiently tracking and facilitating internally redeployment of equipment that is not being used in its current location.

Where an asset can not be relocated, it can be moved through into one of several sales channels. In every case, EquipNet specialists provide expert knowledge and proven project management skills to deliver a complete service package.

Ben Potenza, VP Marketing at EquipNet, said, “Working with both multinational enterprises as well as small and medium sized companies with a single facility, we provide our clients with options to redeploy or sell surplus plant and equipment to gain a real return on their investment.”

To find out more about EquipNet’s asset management expertise and how pharmaceutical industry companies have benefited, visit EquipNet on Booth #1239.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!